设为首页 加入收藏

TOP

外阴和阴道萎缩新药Imvexxy插入物获美国FDA批准(二)
2018-08-13 06:40:41 来源: 作者: 【 】 浏览:1334次 评论:0
Monitor thyroid function. Conditions aggravated by fluid retention. Hypoparathyroidism. Endometriosis. Hereditary angioedema. Asthma. Diabetes. Epilepsy. Migraine. Porphyria. SLE. Hepatic hemangiomas. Do initial complete physical and repeat annually (include Pap smear, mammogram, BP). Reeva luate periodically.
Pharmacological Class:
Estrogen.
Interactions:
May be antagonized by CYP3A4 inducers (eg, St. John's wort, phenobarbital, carbamazepine, rifampin). May be potentiated by CYP3A4 inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice). Concomitant thyroid replacement; may need to increase thyroid dose. May interfere with lab tests (eg, thyroid, PT, coagulation factors, glucose tolerance, HDL/LDL, triglycerides, hormone concentrations, other binding or plasma proteins).
Adverse Reactions:
Headache; thromboembolism, neoplasms.
Generic Availability:
NO
How Supplied:
Vaginal inserts—8, 18
http://www.imvexxy.com/hcp/ 
Tags: 责任编辑:admin
首页 上一页 1 2 下一页 尾页 2/2/2
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇FDA批准新型靶向药Yonsa用于转移.. 下一篇默沙东两款新药elbasvir和grazopr..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位